Copyright
©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 28, 2016; 22(40): 8910-8917
Published online Oct 28, 2016. doi: 10.3748/wjg.v22.i40.8910
Published online Oct 28, 2016. doi: 10.3748/wjg.v22.i40.8910
Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database
Dimas Alexandre Kliemann, Cristiane Valle Tovo, Ana Beatriz Gorini da Veiga, Angelo Alves de Mattos, Graduate Program in Medicine: Hepatology - Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS 90050-170, Brazil
Dimas Alexandre Kliemann, Cristiane Valle Tovo, Hospital Nossa Senhora da Conceição, Porto Alegre, RS 90050-170, Brazil
Ana Beatriz Gorini da Veiga, Department of Basic Health Sciences, Laboratory of Molecular Biology, Graduate Program in Pathology - Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS 90050-170, Brazil
Charles Wood, School of Biological Sciences, Nebraska Center for Virology, University of Nebraska, Lincoln, NE 68511, United States
Author contributions: Kliemann DA designed this study, acquired and analyzed data; Kliemann DA and Wood C interpreted the data; Tovo CV, da Veiga ABG, de Mattos AA and Wood C contributed to writing of article, editing, reviewing and final approval of the article.
Institutional review board statement: The research protocol was approved by the Research Ethics Committee at Hospital Nossa Senhora da Conceição 12089/2012, approval report 12/2012.
Conflict-of-interest statement: The authors declare that no conflict of interest exists.
Data sharing statement: All available data can be obtained by contacting the corresponding author.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dimas Alexandre Kliemann, MD, PhD, Hospital Nossa Senhora da Conceição - Serviço de Infectologia, Av. Francisco Trein, 596, bairro Cristo Redentor, Porto Alegre, Rio Grande do Sul 91350-170, Brazil. dimaskliemann@gmail.com
Telephone: +55-51-3357216 Fax: +55-51-3357216
Received: June 19, 2016
Peer-review started: June 21, 2016
First decision: August 8, 2016
Revised: September 12, 2016
Accepted: September 28, 2016
Article in press: September 28, 2016
Published online: October 28, 2016
Processing time: 129 Days and 12.5 Hours
Peer-review started: June 21, 2016
First decision: August 8, 2016
Revised: September 12, 2016
Accepted: September 28, 2016
Article in press: September 28, 2016
Published online: October 28, 2016
Processing time: 129 Days and 12.5 Hours
Core Tip
Core tip: Chronic hepatitis C virus (HCV) infection is a significant cause of morbidity and mortality. The main therapeutic targets are the NS3/4A protease, NS5B polymerase, and NS5A replication complex. Pre-existence of resistance associated variants to direct antiviral agents (DAA) reduces sustained virologic response rates. Despite the low frequency of mutations, this resistant population is likely to be selected in patients undergoing therapy with DAA. Even though HCV variants resistant to DAA targeting one viral protein remain susceptible to DAA targeting another viral protein, combination therapy could fail due to selection of HCV with resistance substitutions in multiple targets.